Corvus Pharmaceuticals to Present at the Jefferies London Healthcare Conference

Rhea-AI Summary

BURLINGAME, Calif., Nov. 10, 2021 – Corvus Pharmaceuticals (NASDAQ: CRVS) announced its participation at the Jefferies London Healthcare Conference from November 16-19, 2021. The company will engage in one-on-one meetings with investors. Additionally, a pre-recorded corporate overview presentation by CEO Richard A. Miller will be available on-demand starting at 3:00 am ET on November 18. Attendees can register for the webcast here, and the presentation will be accessible for 30 days post-event.

News Market Reaction – CRVS

-4.53%

-4.53% Session move

In the trading session that priced this news, CRVS declined 4.53%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BURLINGAME, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the Jefferies London Healthcare Conference, which is taking place November 16-19, 2021. The Company will conduct one-on-one meetings with investors at this conference and a pre-recorded corporate overview presentation by Richard A. Miller, M.D., president and chief executive officer of Corvus, will be available to play on-demand starting at 3:00 am ET on November 18.

Attendees can register to view the webcast here. A webcast of the presentation will be available via the investor relations section of the Corvus website for 30 days following the event.

About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company. Corvus’ lead product candidate is mupadolimab (CPI-006), a humanized monoclonal antibody directed against CD73 that has exhibited immunomodulatory activity and activation of immune cells in preclinical studies. The Company’s second clinical program, CPI-818, is an investigational, oral, small molecule drug that selectively inhibited ITK in preclinical studies, and is in a multicenter Phase 1/1b clinical trial in patients with several types of T-cell lymphomas. Its third clinical program, ciforadenant (CPI-444), is an oral, small molecule inhibitor of the A2A receptor. For more information, visit www.corvuspharma.com.

INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
llea@corvuspharma.com

MEDIA CONTACT:
Sheryl Seapy
Real Chemistry
+1-949-903-4750
sseapy@realchemistry.com

FAQ

What date will Corvus Pharmaceuticals present at the Jefferies London Healthcare Conference?

Corvus Pharmaceuticals will present at the Jefferies London Healthcare Conference from November 16-19, 2021.

Who will lead the presentation for Corvus Pharmaceuticals?

The presentation will be led by Richard A. Miller, M.D., president and CEO of Corvus Pharmaceuticals.

When will the on-demand presentation by Corvus Pharmaceuticals be available?

The pre-recorded corporate overview presentation will be available on-demand starting at 3:00 am ET on November 18, 2021.

How can I register to view Corvus Pharmaceuticals' presentation?

You can register to view the webcast of Corvus Pharmaceuticals' presentation by clicking here.

How long will the webcast of Corvus Pharmaceuticals' presentation be available?

The webcast will be available for 30 days following the event.